Psilocybin Therapy: How It Works, Who Qualifies, and What to Expect

To get psilocybin treatment in the US today, you have three legal routes: a state-regulated program in Oregon or Colorado for adults 21 and over, which does not require a diagnosis; a clinical trial listed on ClinicalTrials.gov; or New Mexico's medical psilocybin program once it opens, with a statutory deadline of December 31, 2026. Psilocybin therapy, also called psilocybin-assisted therapy, pairs one or two supervised dosing sessions of about 6 to 8 hours with preparation and integration sessions, and no psilocybin product is FDA approved as of November 2026.

Psilocybin has traveled a long road. Once classified alongside heroin as a Schedule I substance with "no accepted medical use," it is now the subject of clinical trials at Johns Hopkins, NYU, Imperial College London and other major research institutions. The FDA has granted it breakthrough therapy designation for depression. Oregon has legalized regulated psilocybin services, and Colorado has followed with its own natural medicine program.

For many people watching this from the sidelines, the question has shifted from "Is this real?" to "How does this actually work, and could it help me?" The answer has four parts: the science behind psilocybin therapy, who is a good candidate, what happens during treatment, and the practical realities of accessing it legally today.

How Psilocybin Works in the Brain

When you ingest psilocybin, your body converts it into psilocin, the compound that is actually active in the brain. Psilocin primarily binds to serotonin 5-HT2A receptors, triggering a cascade of effects that temporarily reshapes how different brain regions communicate with each other. This places psilocybin in the class of classic psychedelics, alongside LSD and DMT, and sets it apart from ketamine, which acts on glutamate NMDA receptors.

The most significant effect, from a therapeutic standpoint, involves the default mode network (DMN). This network is active when we are engaged in self-referential thinking: ruminating, worrying, planning, and maintaining our sense of self. In people with depression, the DMN tends to be overactive, trapping them in loops of negative self-focused thought (1).

Psilocybin temporarily quiets the DMN while increasing connectivity between brain regions that do not normally communicate. Researchers describe this as a more "entropic" or flexible brain state. Old patterns of thought and emotion become less fixed. New connections and perspectives become possible.

Brain imaging studies show that psilocybin increases neural plasticity, the brain's ability to form new connections and reorganize existing ones. According to Doss and colleagues (2021), psilocybin therapy increased cognitive and neural flexibility in people with major depressive disorder. This plasticity effect can persist for weeks to months after the session, creating a window during which therapeutic change is easier to achieve and consolidate (2).

It is important to understand that psilocybin does not "fix" depression the way an antibiotic kills bacteria. Instead, it creates conditions that make psychological change more possible. The therapy that surrounds the experience, both before and after, is what helps translate that potential into lasting improvement.

What the Clinical Evidence Shows

The research on psilocybin for depression has grown rapidly in recent years. The key findings come from randomized trials in treatment-resistant depression, major depressive disorder and cancer-related distress, summarized below.

Treatment-Resistant Depression

A 2022 study published in the New England Journal of Medicine (the COMPASS Pathways trial led by Goodwin and colleagues) tested psilocybin in 233 patients with treatment-resistant depression. The 25mg dose group showed significant improvement at 3 weeks. While the effect moderated over time, it demonstrated that psilocybin could help even patients who had not responded to multiple other treatments (3).

Major Depressive Disorder

A Johns Hopkins trial published in JAMA Psychiatry in 2021 found that two psilocybin sessions (given two weeks apart) produced large, rapid, and sustained antidepressant effects. More than half of participants met criteria for remission at 4 weeks (4).

A later phase 2 trial run by the Usona Institute at 11 research sites in the US, published in JAMA by Raison and colleagues (2023), compared a single dose of psilocybin with a niacin placebo, both given with psychological support, in adults aged 21 to 65 with major depressive disorder. It reported a rapid and sustained reduction in depressive symptoms compared with placebo, and it excluded people with a history of psychosis or mania, active substance use disorder, or active suicidal ideation with intent (11).

Psilocybin vs. SSRIs

A head-to-head comparison with escitalopram (Lexapro) published in the New England Journal of Medicine in 2021 found that psilocybin therapy was at least as effective as the SSRI on the primary measure, and superior on most secondary measures including emotional responsiveness, social functioning, and well-being (5). The trial was small and was not designed to show that psilocybin is better than escitalopram on the main outcome, so it supports psilocybin as a comparable option rather than a replacement.

End-of-Life Distress

Some of the most compelling research involves patients facing terminal illness. Studies at Johns Hopkins and NYU found that a single psilocybin session produced rapid and sustained reductions in depression and anxiety in cancer patients. Effects persisted for years in many participants, with approximately 60% to 80% showing clinically significant improvement at long-term follow-up (6).

Other Conditions Under Investigation

Active research is exploring psilocybin therapy for OCD, alcohol use disorder, tobacco addiction, anorexia nervosa, PTSD, and chronic pain. Results are preliminary but encouraging across several of these areas, and none of these uses is approved. MDMA-assisted therapy is a separate psychedelic treatment studied mainly for PTSD, covered in the research on MDMA therapy for PTSD.

Key psilocybin trials at a glance

The Three Phases of Psilocybin Therapy

Clinical psilocybin therapy is not "take a pill and see what happens." It is a structured process with three distinct phases, preparation, dosing and integration, and each one is essential.

Phase 1: Preparation

Before the dosing session, you will meet with your therapist team (typically two therapists per session in clinical trials) for 2 to 3 preparation sessions, each lasting 1 to 2 hours. In Oregon and Colorado, a state-licensed facilitator, who may or may not be a licensed mental health clinician, usually leads preparation instead.

During preparation, you will:

• Build therapeutic rapport. Feeling safe with your therapists is critical because the psilocybin session can bring up vulnerable, emotional material. You need to trust the people in the room.
• Discuss your history and intentions. What brought you to this treatment? What are you hoping to work through? What feels most stuck in your life right now?
• Learn what to expect. Your therapists will walk you through the timeline of the experience, possible effects (both pleasant and challenging), and techniques for working with difficult emotions.
• Develop a framework. Most programs teach an approach of "trust, let go, be open." When challenging experiences arise during the session, the guidance is to move toward them rather than resist.
• Address fears. Many people are anxious about losing control, having a "bad trip," or confronting painful memories. These concerns are normal and worth discussing openly.

Phase 2: The Dosing Session

The session itself typically lasts 6 to 8 hours and takes place in a comfortable room designed to feel warm and safe rather than clinical. Here is what actually happens.

The setting. You will be in a room with comfortable furnishings, often a couch or reclining bed. Lighting is soft. Two therapists are present throughout. Emergency medical equipment is available but rarely needed.

Taking the psilocybin. You will swallow a capsule containing a measured dose of synthetic psilocybin (most clinical trials use 25mg, equivalent to roughly 3 to 5 grams of dried mushrooms). Some programs use a lower dose for the first session and a higher dose for the second. Oregon service centers use products from licensed manufacturers, often whole mushroom products rather than synthetic capsules.

The onset (30 to 60 minutes). Effects begin gradually with changes in visual perception (colors becoming more vivid, patterns appearing), emotional sensitivity, and a shift in the quality of your thoughts. Some people feel nauseous during onset; this usually passes.

The peak experience (2 to 4 hours). This is the most intense phase. Experiences vary enormously between individuals, but commonly include:

• Deep emotional processing, sometimes involving tears, laughter, or both
• A sense of connection to something larger than oneself
• Revisiting and reprocessing difficult memories with new perspective
• Visual phenomena (patterns, colors, meaningful imagery)
• Feelings of love, grief, awe, fear, or peace, sometimes in rapid succession
• Moments of profound insight about personal patterns or relationships

The come-down (2 to 3 hours). The intensity gradually decreases. Many people feel emotionally open and reflective during this phase. Therapists may begin light conversation about what came up during the experience. You should not drive afterward, so programs ask you to arrange a ride home.

During the session, therapists take a primarily non-directive approach. They do not analyze your experience in real time or guide you toward specific insights. Instead, they provide a safe container and gentle encouragement: "You're doing great. It's safe to stay with that feeling." If you become frightened, they are there to reassure you and help you stay present rather than retreating (7).

Eye shades and music are used in most protocols. The eye shades encourage an inward focus rather than external visual distraction. The music (typically instrumental, carefully curated playlists that arc from grounding to expansive and back) provides emotional scaffolding for the experience.

Phase 3: Integration

Integration sessions begin within days of the dosing session and continue for weeks afterward. This is where lasting change is built.

During integration, you will:

• Process the experience. What happened? What emotions came up? What did you see, feel, or understand? Not everything that happens during a psilocybin session is immediately meaningful, and not every insight translates directly into action. Integration helps you sort through it.
• Identify actionable insights. Maybe you realized how much resentment you have been carrying toward a parent. Maybe you felt a deep sense of self-compassion for the first time. Integration helps you figure out what to do with these realizations.
• Develop new practices. Meditation, journaling, changes in relationships, shifts in how you handle stress. The increased neural plasticity from psilocybin creates a window where new habits are easier to establish.
• Address difficult material. Sometimes psilocybin surfaces painful truths that need further therapeutic work. Integration provides space for this processing.

Most programs include 2 to 4 integration sessions, but many therapists recommend ongoing integration support for weeks or months. Some patients continue with regular therapy using the insights from their psilocybin experience as a foundation. Oregon's model offers an integration session but does not require one, so people using a state program often arrange integration with their own psychotherapist or psychiatrist.

Who Qualifies (and Who Doesn't)

Who qualifies for psilocybin therapy depends on the route. Clinical trials screen for a specific diagnosis such as major depressive disorder, while Oregon and Colorado screen adults 21 and over for safety without requiring any diagnosis.

Good Candidates

Based on current clinical trial criteria and clinical practice guidelines, psilocybin therapy may be appropriate for:

• Adults with major depressive disorder, especially treatment-resistant depression
• People who have tried conventional treatments without adequate improvement
• Patients with depression or anxiety related to serious medical illness
• Adults who are psychologically stable enough to tolerate an intense emotional experience
• People who can commit to the full preparation, session and integration process

Contraindications

Certain people should not receive psilocybin therapy:

• Personal or family history of psychotic disorders (schizophrenia, schizoaffective disorder, bipolar I with psychotic features). This is the strongest contraindication and is essentially absolute (8).
• Uncontrolled cardiovascular conditions. Psilocybin temporarily increases heart rate and blood pressure.
• Current use of lithium. The combination carries risk of seizures.
• Current use of SSRIs or SNRIs (may need to taper under medical supervision before treatment, as these medications can block or reduce psilocybin's effects).
• Active suicidal ideation with intent. While psilocybin shows promise for suicidal depression, current protocols typically exclude actively suicidal patients due to safety concerns during the acute experience.
• Pregnancy or breastfeeding.

Who screens you

In a clinical trial, a study psychiatrist or physician screens you with a psychiatric interview, a medical history, a medication review and often an ECG and blood work. In Oregon and Colorado, a licensed facilitator reviews a client information form covering mental health history, medications and physical conditions, and can decline or refer people for whom the risks look too high. A state program screening is a safety check, not a medical evaluation, so a conversation with your own prescriber is still worthwhile.

How to Get Psilocybin Treatment in the US

Getting psilocybin treatment legally in the US means choosing one of three routes: enrolling in a clinical trial, using a licensed state program in Oregon or Colorado, or, once it opens, New Mexico's medical psilocybin program. Psilocybin remains a Schedule I controlled substance under federal law, so a doctor cannot prescribe it and a pharmacy cannot dispense it outside these routes.

1. Talk with your current prescriber first. A psychiatrist, primary care physician or psychiatric nurse practitioner can review your diagnosis, your heart health and medications such as SSRIs, SNRIs and lithium before you apply anywhere.
2. Pick the route that fits your situation. A trial suits people with a qualifying diagnosis who can travel to a research site; a state program suits adults 21 and over who can pay out of pocket and travel to Oregon or Colorado.
3. For a clinical trial, search the federal registry. Search ClinicalTrials.gov for psilocybin studies, filter for studies that are recruiting near you, and contact the listed study coordinator. Expect several screening visits before you are accepted.
4. For Oregon, find a licensed service center. The Oregon Health Authority's Oregon Psilocybin Services section licenses service centers and facilitators. You complete a preparation session with a licensed facilitator, then an administration session at the service center.
5. For Colorado, check both licenses. The Colorado Department of Revenue's Natural Medicine Division licenses healing centers, and the Department of Regulatory Agencies licenses facilitators. Ask for both license numbers and check them on the state lookups.
6. Plan integration and follow-up care. Arrange integration sessions and ongoing care with a mental health clinician before the dosing day, especially if you used a state program that does not require integration.

Legal routes to psilocybin therapy compared

Finding psychedelic therapy providers near you

The Regenerated.com directory lists psychedelic therapy clinics across the US, with state pages for psychedelic therapy providers in Oregon and licensed natural medicine options in Colorado. Many listed practices offer ketamine-assisted therapy or integration support rather than psilocybin sessions, so confirm exactly which service and which license a clinic holds before you book. For background on the wider treatment category, read our psychedelic therapy treatment guide.

Listing order on Regenerated.com is not paid ranking. Featured slots are labeled and capped, Verified means a clinic has completed credential checks rather than paid for placement, and the directory is free for patients to use. Inclusion in the directory is not an endorsement, and the difference between Featured, Verified and organic listings is explained in full in our guide.

Cost and Access

Oregon Psilocybin Services

Oregon's regulated psilocybin program, created by Ballot Measure 109 in 2020, began accepting clients in 2023. Licensed service centers offer supervised psilocybin sessions. A full course of treatment (preparation, dosing session, integration) typically costs $1,500 to $3,500. Insurance does not currently cover it.

Oregon's program does not require a diagnosis or medical referral. It is a supervised wellness model, not a medical model. This means any adult 21 or over who passes screening can access it, but it also means there is less clinical structure than in a medical setting.

Clinical Trials

Participating in a clinical trial is another option, often at no cost. ClinicalTrials.gov lists active psilocybin studies. Major research centers running trials include Johns Hopkins, NYU, UCSF, Yale, and Imperial College London. Enrollment criteria are strict, but for those who qualify, it provides access to high-quality treatment. Some participants receive a placebo or a low comparison dose, and some studies offer an open-label psilocybin session afterward.

Colorado's Natural Medicine Program

Colorado voters approved the Natural Medicine Health Act (Proposition 122) in 2022, and the state issued its first healing center license in 2025. Adults 21 and over can now receive psilocybin services from a licensed facilitator at a licensed healing center, without a diagnosis or referral. As with Oregon, sessions are cash pay and insurance does not cover them.

New Mexico's Medical Psilocybin Program

New Mexico's Medical Psilocybin Act, signed in 2025, creates a medical program run by the state Department of Health for qualifying conditions including treatment-resistant major depression, PTSD, substance use disorders and end-of-life care. The law sets a deadline of December 31, 2026 for the program to begin. Unlike Oregon and Colorado, it requires a clinician to certify that you have a qualifying condition.

Federal Status and FDA Review

No psilocybin product is FDA approved as of November 2026, and psilocybin remains a Schedule I controlled substance under federal law. The FDA has granted breakthrough therapy designation to psilocybin programs for depression, and sponsors including Compass Pathways (for treatment-resistant depression) and the Usona Institute (for major depressive disorder) have moved to new drug applications. Any approved product would still need rescheduling by the DEA, and would likely come with a REMS safety program that limits where it can be given.

Does insurance cover psilocybin therapy?

Insurance does not cover psilocybin services in Oregon or Colorado. Therapy sessions with your own licensed clinician before or after may be billable to insurance, but the psilocybin session itself is paid out of pocket. Coverage could change if an FDA-approved product reaches the market.

Underground and International Options

Some people seek psilocybin therapy through underground providers or international retreats (Jamaica, the Netherlands, and Costa Rica are common destinations). While these options exist, they come with significant risks: variable quality of facilitation, no medical oversight, no legal recourse if something goes wrong, and no standardized protocols (9).

What Results to Expect

Setting realistic expectations is important. Here is what the research suggests.

Rapid onset. Unlike SSRIs, which take weeks, many psilocybin therapy participants notice meaningful shifts within days of their session.

Significant but variable magnitude. In clinical trials, roughly 50% to 70% of participants show meaningful improvement, and 25% to 50% achieve full remission. These figures come from small, closely supervised trials with carefully screened volunteers, so they are not directly comparable with results from everyday antidepressant care, and they are not 100%.

Duration varies. Some participants maintain improvement for months or years after a single treatment course. Others experience gradual return of symptoms after weeks or months. The field is still working out optimal retreatment protocols.

Not always comfortable. The most therapeutically productive psilocybin sessions are not always pleasant. Confronting the sources of your depression can be painful. Many patients describe the experience as one of the most difficult and most meaningful of their lives (10).

Integration makes the difference. Participants who engage actively in integration work tend to have better long-term outcomes than those who do not. The experience opens a door, but you have to walk through it.

Side Effects and Risks of Psilocybin Therapy

Psilocybin therapy causes short-term side effects in many people and carries rare but serious risks, which is why screening and supervision matter. Most side effects in clinical trials were mild to moderate and faded within a day.

• During the session: anxiety or fear, confusion, nausea, and a temporary rise in heart rate and blood pressure.
• In the following day or two: headache and fatigue are the most commonly reported effects.
• Psychological risks: distressing experiences, and in people with a personal or family history of psychosis, a risk of triggering a psychotic episode.
• Suicidal thoughts: the 2022 New England Journal of Medicine trial in treatment-resistant depression reported suicidal ideation or self-harm in some participants across dose groups, which is why follow-up care after dosing matters.
• Without supervision: risky behavior while intoxicated, and unknown dose or contents in unregulated mushrooms.

Psilocybin has low potential for physical dependence, according to an analysis of its abuse potential by Johnson and colleagues (2018), but it is still a powerful drug that should be taken only with trained support (8).

Psilocybin Therapy vs. Ketamine, Esketamine and TMS

Psilocybin therapy is one of several options for depression that has not responded to standard antidepressants. The others are available now through regular medical care, and some are covered by insurance.

If psilocybin is not available to you, ketamine therapy for depression and TMS treatment are the closest established alternatives, and you can browse ketamine clinics in the directory. Our comparison of Spravato versus IV ketamine explains how those two differ.

The Bottom Line

Psilocybin therapy represents a genuinely different approach to treating depression, one that works through a single or few sessions rather than daily medication, that targets the psychological and neural roots of depression rather than just managing symptoms, and that empowers patients to be active participants in their own healing.

The evidence is strong and growing, but it is not a magic solution. It works best for certain people, requires skilled therapeutic support, carries real contraindications, and demands personal commitment to the integration process.

If conventional treatments have not given you the relief you need, psilocybin therapy is worth exploring, through legal channels, with qualified providers, and with eyes open about both its potential and its limitations. Today those legal channels are clinical trials, Oregon Psilocybin Services and Colorado's licensed healing centers, with New Mexico's medical program next.

For the broader context on psychedelic-assisted treatments, visit our psychedelic therapy pillar page.

Frequently Asked Questions

Does psilocybin therapy actually work for depression?

Psilocybin therapy has shown strong early results for depression, but the evidence is still building. Across trials, roughly 50% to 70% of participants showed meaningful improvement and 25% to 50% reached remission. The 2022 COMPASS Pathways trial of 233 people with treatment-resistant depression found significant improvement at 3 weeks with the 25mg dose, and a 2021 Johns Hopkins trial found more than half of participants in remission at 4 weeks. Effects can fade over time, and larger, longer trials are still under way.

How much does psilocybin therapy cost, and does insurance cover it?

In Oregon, a full course of psilocybin services covering preparation, the dosing session and integration typically costs $1,500 to $3,500, and insurance does not currently cover it. Colorado healing centers are also cash pay, with prices set by each center. Clinical trials are usually free for participants. If the FDA approves a psilocybin product, coverage will depend on each insurer, so ask any provider for an itemized quote before you commit.

How long does a session take and how soon does it work?

A psilocybin dosing session lasts about 6 to 8 hours. Effects begin 30 to 60 minutes after the dose, peak at 2 to 4 hours and fade over another 2 to 3 hours. A full course usually adds 2 to 3 preparation sessions beforehand and 2 to 4 integration sessions afterward. Many trial participants noticed changes within days, and some kept their improvement for months or years, while others saw symptoms return after weeks or months.

Is psilocybin therapy safe, and what are the risks?

Psilocybin therapy carries real risks and is not appropriate for everyone. The strongest contraindication is a personal or family history of psychotic disorders such as schizophrenia or bipolar I with psychotic features. Lithium use, uncontrolled heart conditions, active suicidal intent, pregnancy and breastfeeding also exclude most people. Common short-term effects include anxiety, headache, nausea and raised blood pressure. Underground and overseas options add risk through variable facilitation, no medical oversight and no legal recourse.

Is psilocybin therapy legal and FDA approved?

Psilocybin is not FDA approved as of November 2026 and remains a Schedule I controlled substance under federal law, although the FDA has granted it breakthrough therapy designation for depression and new drug applications are under review. Oregon has run regulated psilocybin services since 2023, Colorado licenses healing centers for adults 21 and over, and New Mexico's medical program is due by December 31, 2026. Clinical trials are the other legal route to treatment.

Who is psilocybin therapy for, and does it interact with antidepressants?

Psilocybin therapy is mainly studied in adults with major depressive disorder, especially those who have tried conventional treatments without enough relief, who are psychologically stable enough for an intense experience, and who can commit to preparation and integration. SSRIs and SNRIs can block or reduce psilocybin's effects, so some programs ask people to taper first, which should happen only under the prescriber's supervision. Lithium is a firm exclusion because of seizure risk.

Sources

1. Carhart-Harris RL, Friston KJ. (2019). REBUS and the anarchic brain: toward a unified model of the brain action of psychedelics. Pharmacological Reviews, 71(3), 316-344. doi:10.1124/pr.118.017160 ↩
2. Doss MK, et al. (2021). Psilocybin therapy increases cognitive and neural flexibility in patients with major depressive disorder. Translational Psychiatry, 11(1), 574. doi:10.1038/s41398-021-01706-y ↩
3. Goodwin GM, et al. (2022). Single-dose psilocybin for a treatment-resistant episode of major depression. New England Journal of Medicine, 387(18), 1637-1648. doi:10.1056/NEJMoa2206443 ↩
4. Davis AK, et al. (2021). Effects of psilocybin-assisted therapy on major depressive disorder: a randomized clinical trial. JAMA Psychiatry, 78(5), 481-489. doi:10.1001/jamapsychiatry.2020.3285 ↩
5. Carhart-Harris R, et al. (2021). Trial of psilocybin versus escitalopram for depression. New England Journal of Medicine, 384(15), 1402-1411. doi:10.1056/NEJMoa2032994 ↩
6. Agin-Liebes GI, et al. (2020). Long-term follow-up of psilocybin-assisted psychotherapy for psychiatric and existential distress in patients with life-threatening cancer. Journal of Psychopharmacology, 34(2), 155-166. doi:10.1177/0269881119897615 ↩
7. Johnson MW, Richards WA, Griffiths RR. (2008). Human hallucinogen research: guidelines for safety. Journal of Psychopharmacology, 22(6), 603-620. doi:10.1177/0269881108093587 ↩
8. Johnson MW, Griffiths RR, Hendricks PS, Henningfield JE. (2018). The abuse potential of medical psilocybin according to the 8 factors of the Controlled Substances Act. Neuropharmacology, 142, 143-166. doi:10.1016/j.neuropharm.2018.05.012 ↩
9. Schenberg EE. (2018). Psychedelic-assisted psychotherapy: a paradigm shift in psychiatric research and development. Frontiers in Pharmacology, 9, 733. doi:10.3389/fphar.2018.00733 ↩
10. Griffiths RR, et al. (2016). Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: a randomized double-blind trial. Journal of Psychopharmacology, 30(12), 1181-1197. doi:10.1177/0269881116675513 ↩
11. Raison CL, et al. (2023). Single-dose psilocybin treatment for major depressive disorder: a randomized clinical trial. JAMA, 330(9), 843-853. PubMed 37651119 ↩

Related Reading

• Psychedelic Therapy for Depression: What the Research Shows
• Complete Guide to Psychedelic Therapy
• Biofeedback for Anxiety: How It Works
• Regenerative Medicine for Longevity
• Stem Cell Therapy Overview
• Ketamine for Depression